Diagnosis of invasive fungal infections in hematology and oncology-guidelines from the infectious diseases working party in Haematology and oncology of the German Society for Haematology and oncology (AGIHO)

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 823-833

  Ruhnke, M ^a   Bohme A ^b   Buchheidt, D ^c   Cornely, O ^d   Donhuijsen, K ^e   Einsele, H ^f   Enzensberger, R ^g   Hebart, H ^h   Heussel, C P ⁱ   Horger, M ^j   Hof, H ^k   Karthaus, M ^l   Kruger W ^m   Maschmeyer, G ⁿ   Penack, O ^a   Ritter, J ^o   Schwartz, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Onkologikum Frankfurt Am Museumsufer   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e Academic Hospital   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h Department of Haematology and Oncology   (Germany)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k Labor Limbach   (Germany)

^l Municipal Hospital Neuperlach   (Germany)

^m UNIVERSITY OF GREIFSWALD   (Germany)

ⁿ KLINIKUM ERNST VON BERGMANN   (Germany)

^o UNIVERSITY HOSPITAL MÜNSTER   (Germany)

more..

Author keywords

Cancer; Diagnosis; Fungal infections; Granulocytopenia; Hematology; Recommendations

Indexed keywords

ANTIFUNGAL AGENT; FUNGAL DNA; FUNGUS ANTIBODY; FUNGUS ANTIGEN;

ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DETECTION; ANTIGEN DETECTION; BIOMICROSCOPY; BIOPSY TECHNIQUE; BLOOD ANALYSIS; BODY FLUID; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG EFFECT; ENDOSCOPY; EVIDENCE BASED MEDICINE; FUNGUS CULTURE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOASSAY; INFECTION PREVENTION; INFECTION RISK; METABOLITE; MOLECULAR DIAGNOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; SYSTEMIC MYCOSIS; SYSTEMIC THERAPY;

HEMATOLOGIC NEOPLASMS; HEMATOLOGY; HUMANS; LUNG DISEASES, FUNGAL; MEDICAL ONCOLOGY; OPPORTUNISTIC INFECTIONS;

EID: 84859500670     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr407     Document Type: Review

References (126)

1. Ninin E, Milpied N, Moreau P et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001; 33(1): 41-47.
2. Upton A, Kirby KA, Carpenter P et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44(4): 531-540.
3. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45(9): 1161-1170.
4. Ruhnke M, Böhme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S141-S148.
5. Penack O, Buchheidt D, Christopeit M et al. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol 2011; 22(5): 1019-1029.
6. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S133-S140.
7. Kish M A. Guide to development of practice guidelines. Clin Infect Dis 2001; 32(6): 851-854.
8. Ascioglu S, Rex JH, De Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34(1): 7-14.
9. dePauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46(12): 1813-1821.
10. Subira M, Martino R, Rovira M et al. Clinical applicability of the new EORTC/ MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003; 82(2): 80-82.
11. Cornely OA, Bohme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94(1): 113-122.
12. Galimberti R, Kowalczuk A, Hidalgo Parra I et al. Cutaneous aspergillosis: a report of six cases. Br J Dermatol 1998; 139(3): 522-556.
13. Hagensee ME, Bauwens JE, Kjos B, Bowden R A. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994; 19(3): 402-408.
14. Andreas S, Heindl S, Wattky C et al. Diagnosis of pulmonary aspergillosis using optical brighteners. Eur Respir J 2000; 15(2): 407-411.
15. Hayden RT, Isotalo P A, Parrett T et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 2003; 12(1): 21-26.
16. Buchheidt D, Hummel M, Schleiermacher D et al. Current molecular diagnostic approaches to systemic infections with Aspergillus species in patients with hematological malignancies. Leuk Lymphoma 2004; 45(3): 463-468.
17. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006; 42(4): 487-489.
18. Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11(2): 99-109.
19. Jones JM. Laboratory diagnosis of invasive candidiasis. Clin Microbiol Rev 1990; 3(1): 32-45.
20. Ness MJ, Vaughan WP, Woods GL. Candida antigen latex test for detection of invasive candidiasis in immunocompromised patients. J Infect Dis 1989; 159(3): 495-502.
21. McDonald LC, Weinstein MP, Fune J et al. Controlled comparison of BacT/ ALERT FAN aerobic medium and BATEC fungal blood culture medium for detection of fungemia. J Clin Microbiol 2001; 39(2): 622-624.
22. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev 1997; 10(3): 444-465.
23. Meyer MH, Letscher-Bru V, Jaulhac B et al. Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the bactec 9240 system. J Clin Microbiol 2004; 42(2): 773-777.
24. Morrell RM Jr, Wasilauskas BL, Steffee CH. Performance of fungal blood cultures by using the isolator collection system: is it cost-effective? J Clin Microbiol 1996; 34(12): 3040-3043.
25. Hamilton JR, Noble A, Denning DW, Stevens DA. Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol 1991; 29(2): 333-339.
26. Perfect JR, Cox GM, Lee JY et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33(11): 1824-1833.
27. Sandford GR, Merz W G, Wingard JR et al. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142(4): 503-509.
28. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3(12): 772-785.
29. Pittet D, Monod M, Suter PM et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220(6): 751-758.
30. Piarroux R, Grenouillet F, Balvay P et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32(12): 2443-2449.
31. Wingard JR, Merz WG, Saral R. Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med 1979; 91(4): 539-543.
32. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20(1): 115-125.
33. Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28(5): 1071-1079.
34. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38(2): 161-189.
35. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48(5): 503-535.
36. Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 1994; 32(8): 1923-1929.
37. Marklein G, Josten M, Klanke U et al. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol 2009; 47(9): 2912-2917.
38. Kauffman CA. Candiduria. Clin Infect Dis 2005; 41 (Suppl 6): S371-S376.
39. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards 1997.
40. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, NCCLS document M38-A. Approved Standard. Wayne, PA: National Committee for Clinical Laboratory Standards 2002.
41. Cuenca-Estrella M, Moore C B, Barchiesi F et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2003; 9(6): 467-474.
42. Rex JH, Pfaller MA, Barry AL et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39(1): 40-44.
43. Espinel-Ingroff A. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B. J Clin Microbiol 2006; 44(10): 3616-3622.
44. de Repentigny L. Serodiagnosis of candidiasis, aspergillosis, and cryptococcosis. Clin Infect Dis 1992; 14 (Suppl 1): S11-S22.
45. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321(12): 794-799.
46. Burnie JP, Williams JD. Evaluation of the Ramco latex agglutination test in the early diagnosis of systemic candidiasis. Eur J Clin Microbiol 1985; 4(2): 98-101.
47. Fung JC, Donta ST, Tilton RC. Candida detection system (CAND-TEC) to differentiate between Candida albicans colonization and disease. J Clin Microbiol 1986; 24(4): 542-547.
48. Sendid B, Caillot D, Baccouch-Humbert B et al. Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 2003; 41(10): 4551-4558.
49. Yera H, Sendid B, Francois N et al. Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis 2001; 20(12): 864-870.
50. Lunel FM, Mennink-Kersten MA, Ruegebrink D et al. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn Microbiol Infect Dis 2009; 64(4): 408-415.
51. Mikulska M, Calandra T, Sanguinetti M et al. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010; 14(6): R222.
52. Kappe R, Schulze-Berge A, Sonntag HG. Evaluation of eight antibody tests and one antigen test for the diagnosis of invasive aspergillosis. Mycoses 1996; 39(1-2): 13-23.
53. Maertens J, Verhaegen J, Demuynck H et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999; 37(10): 3223-3228.
54. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41(9): 1242-1250.
55. Maertens J, Theunissen K, Verbeken E et al. Prospective clinical evaluation of lower cutoffs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126(6): 852-860.
56. Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97(6): 1604-1610.
57. Sulahian A, Tabouret M, Ribaud P et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996; 15(2): 139-145.
58. Sulahian A, Boutboul F, Ribaud P et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer 2001; 91(2): 311-318.
59. Marr KA, Balajee SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190(3): 641-649.
60. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4(6): 349-357.
61. Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349(24): 2366-2367.
62. Penack O, Rempf P, Graf B et al. False-positive Aspergillus antigen testing due to application of piperacillin/tazobactam-is it still an issue? Diagn Microbiol Infect Dis 2008; 60(1): 117-120.
63. Penack O, Schwartz S, Thiel E, Wolfgang BI. Lack of evidence that falsepositive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam. Clin Infect Dis 2004; 39(9): 1401-1402.
64. Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 2008; 27(4): 245-251.
65. Maertens J, Buve K, Theunissen K et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2009; 115(2): 355-362.
66. Pazos C, del PA. [Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by Platelia Aspergillus]. Rev Iberoam Micol 2003; 20(3): 99-102.
67. Girmenia C, Micozzi A, Gentile G et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28(4): 667-674.
68. Yoshida M, Obayashi T, Iwama A et al. Detection of plasma (1->3)-beta-Dglucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol 1997; 35(5): 371-374.
69. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39(2): 199-205.
70. Obayashi T, Yoshida M, Mori T et al. Plasma (1->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345(8941): 17-20.
71. Pazos C, Ponton J, del PA.. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43(1): 299-305.
72. Hachem RY, Kontoyiannis DP, Chemaly R F et al. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009; 47(1): 129-133.
73. Senn L, Robinson JO, Schmidt S et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46(6): 878-885.
74. Oude Nijhuis CS, Gietema JA, Vellenga E et al. Routine radiography does not have a role in the diagnostic evaluation of ambulatory adult febrile neutropenic cancer patients. Eur J Cancer 2003; 39(17): 2495-2498.
75. Heussel CP, Kauczor HU, Heussel G et al. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. AJR Am J Roentgenol 1997; 169(5): 1347-1353.
76. Heussel CP, Kauczor HU, Heussel GE et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999; 17(3): 796-805.
77. Ramila E, Sureda A, Martino R et al. Bronchoscopy guided by high-resolution computed tomography for the diagnosis of pulmonary infections in patients with hematologic malignancies and normal plain chest X-ray. Haematologica 2000; 85(9): 961-966.
78. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patientswith neutropenia. J Clin Oncol 2001; 19(1): 253-259.
79. Horger M, Hebart H, Einsele H et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome? Eur J Radiol 2005; 55(3): 437-444.
80. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44(3): 373-379.
81. Kami M, Kishi Y, Hamaki T et al. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsybased retrospective study of 48 patients. Mycoses 2002; 45(8): 287-294.
82. Kim Y, Lee K S, Jung K J et al. Halo sign on high resolution CT: findings in spectrum of pulmonary diseases with pathologic correlation. J Comput Assist Tomogr 1999; 23(4): 622-626.
83. Lass-Flörl C, Resch G, Nachbaur D et al. The value of computed tomographyguided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45(7): e101-e104.
84. Horger M, Einsele H, Schumacher U et al. Invasive pulmonary aspergillosis: frequency and meaning of the "hypodense sign" on unenhanced CT. Br J Radiol 2005; 78(932): 697-703.
85. Brodoefel H, Vogel M, Hebart H et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. AJR Am J Roentgenol 2006; 187(2): 404-413.
86. Karthaus M, Huebner G, Elser C et al. Early detection of chronic disseminated Candida infection in leukemia patients with febrile neutropenia: value of computerassisted serial ultrasound documentation. Ann Hematol 1998; 77(1-2): 41-45.
87. Karthaus M, Huebner G, Geissler R G et al. Hepatic lesions of chronic disseminated systemic candidiasis in leukemia patients may become visible during neutropenia: value of serial ultrasound examinations. Blood 1998; 91(8): 3087-3089.
88. Semelka RC, Shoenut JP, Greenberg HM, Bow EJ. Detection of acute and treated lesions of hepatosplenic candidiasis: comparison of dynamic contrastenhanced CT and MR imaging. J Magn Reson Imaging 1992; 2(3): 341-345.
89. Semelka RC, Kelekis NL, Sallah S et al. Hepatosplenic fungal disease: diagnostic accuracy and spectrum of appearances on MR imaging. AJR Am J Roentgenol 1997; 169(5): 1311-1316.
90. Rudolph J, Rodenwaldt J, Ruhnke M et al. Unusual enhancement pattern of liver lesions in hepatosplenic candidiasis. Acta Radiol 2004; 45(5): 499-503.
91. Teyton P, Baillet G, Hindie E et al. Hepatosplenic candidiasis imaged with F-18 FDG PET/CT. Clin Nucl Med 2009; 34(7): 439-440.
92. Horger M, Hebart H, Schimmel H et al. Disseminated mucormycosis in haematological patients: CT and MRI findings with pathological correlation. Br J Radiol 2006; 79(945): e88-e95.
93. Schmit M, Bethge W, Beck R et al. CT of gastrointestinal complications associated with hematopoietic stem cell transplantation. AJR Am J Roentgenol 2008; 190(3): 712-719.
94. Buchheidt D, Böhme A, Cornely OA et al. Diagnosis and treatment of documented infections in neutropenic patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S127-S132.
95. Dietrich U, Hettmann M, Maschke M et al. Cerebral aspergillosis: comparison of radiological and neuropathologic findings in patients with bone marrow transplantation. Eur Radiol 2001; 11(7): 1242-1249.
96. Maschke M, Dietrich U, PrumbaumMet al. Opportunistic CNS infection after bone marrow transplantation. Bone Marrow Transplant 1999; 23(11): 1167-1176.
97. Guermazi A, Gluckman E, Tabti B, Miaux Y. Invasive central nervous system aspergillosis in bone marrow transplantation recipients: an overview. Eur Radiol 2003; 13(2): 377-388.
98. Aribandi M, McCoy VA, Bazan C III. Imaging features of invasive and noninvasive fungal sinusitis: a review. Radiographics 2007; 27(5): 1283-1296.
99. Hohenadel I A, Kiworr M, Genitsariotis R et al. Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen. Thorax 2001; 56(2): 115-120.
100. Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009; 45(14): 2462-2472.
101. Gillespie MB, O'Malley BW Jr, Francis HW. An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host. Arch Otolaryngol Head Neck Surg 1998; 124(5): 520-526.
102. Gorschlüter M, Mey U, Strehl J et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006; 6: 35.
103. Ustun C. Laparoscopic appendectomy in a patient with acute myelogenous leukemia with neutropenia. J Laparoendosc Adv Surg Tech A 2007; 17(2): 213-215.
104. Anttila V J, Farkkila M, Jansson SE et al. Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis. Eur J Clin Microbiol Infect Dis 1997; 16(9): 637-643.
105. Phillips EH, Carroll BJ, Chandra M et al. Laparoscopic-guided biopsy for diagnosis of hepatic candidiasis. J Laparoendosc Surg 1992; 2(1): 33-38.
106. Carrafiello G, Lagana D, Nosari A M et al. Utility of computed tomography (CT) and of fine needle aspiration biopsy (FNAB) in early diagnosis of fungal pulmonary infections. Study of infections from filamentous fungi in haematologically immunodeficient patients. Radiol Med 2006; 111(1): 33-41.
107. Rickerts V, Mousset S, Lambrecht E et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44(8): 1078-1083.
108. Anttila VJ, Elonen E, Nordling S et al. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 1997; 24(3): 375-380.
109. Buchman TG, Rossier M, Merz WG, Charache P. Detection of surgical pathogens by in vitro DNA amplification. Part I. Rapid identification of Candida albicans by in vitro amplification of a fungus-specific gene. Surgery 1990; 108(2): 338-346.
110. Einsele H, Hebart H, Roller G et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997; 35(6): 1353-1360.
111. Einsele H, Quabeck K, Müller KD et al. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet 1998; 352(9138): 1443.
112. Hebart H, Löffler J, Meisner C et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181(5): 1713-1719.
113. Hebart H, Löffler J, Reitze H et al. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol 2000; 111(2): 635-640.
114. Lass-Flörl C, Aigner J, Gunsilius E et al. Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol 2001; 113(1): 180-184.
115. Jordanides NE, Allan EK, McLintock L A et al. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haematooncology patients. Bone Marrow Transplant 2005; 35(4): 389-395.
116. McLintock LA, Jordanides NE, Allan E K et al. The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br J Haematol 2004; 124(3): 403-404.
117. Buchheidt D, Baust C, Skladny H et al. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 2002; 116(4): 803-811.
118. Buchheidt D, Baust C, Skladny H et al. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results. Clin Infect Dis 2001; 33(4): 428-435.
119. Skladny H, Buchheidt D, Baust C et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol 1999; 37(12): 3865-3871.
120. Buchheidt D, Hummel M, Schleiermacher D et al. Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 125(2): 196-202.
121. Costa C, Costa JM, Desterke C et al. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzymelinked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002; 40(6): 2224-2227.
122. Kami M, Fukui T, Ogawa S et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33(9): 1504-1512.
123. White PL, Barton R, Guiver M et al. A consensus on fungal polymerase chain reaction diagnosis?: a United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. J Mol Diagn 2006; 8(3): 376-384.
124. White PL, Bretagne S, Klingspor L et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48(4): 1231-1240.
125. Bretagne S, Costa JM, Bart-Delabesse E et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998; 26(6): 1407-1412.
126. Kawazu M, Kanda Y, Nannya Y et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42(6): 2733-2741.